安图生物
(603658)
| 流通市值：227.20亿 | | | 总市值：227.20亿 |
| 流通股本：5.71亿 | | | 总股本：5.71亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 3,239,525,111.2 | 2,057,927,123.1 | 992,202,191.51 | 4,226,413,277.24 |
| 营业收入 | 3,239,525,111.2 | 2,057,927,123.1 | 992,202,191.51 | 4,226,413,277.24 |
| 二、营业总成本 | 2,367,660,745.1 | 1,551,661,922.35 | 758,254,185.72 | 3,171,017,904.49 |
| 营业成本 | 1,018,532,436.42 | 674,033,046.31 | 330,992,970.52 | 1,452,300,743.96 |
| 税金及附加 | 50,480,213.88 | 32,626,051.47 | 15,916,555.61 | 62,570,065.66 |
| 销售费用 | 608,857,437.38 | 393,152,546.97 | 198,459,731.57 | 850,346,611.64 |
| 管理费用 | 202,014,890.12 | 132,340,943.14 | 70,708,301.98 | 241,291,919.7 |
| 研发费用 | 464,815,042.55 | 302,352,829.31 | 134,113,720.19 | 555,115,864.12 |
| 财务费用 | 22,960,724.75 | 17,156,505.15 | 8,062,905.85 | 9,392,699.41 |
| 其中:利息费用 | 7,274,369.12 | 5,993,474.69 | 2,725,390.3 | 13,958,489.76 |
| 其中:利息收入 | 12,299,862.81 | 8,700,228.11 | 3,584,259.67 | 7,079,028.42 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 1,088,630.62 | 28,802.44 | 1,201,247.29 | -3,495,613.67 |
| 加:投资收益 | 39,320,816.22 | 29,718,977.45 | 19,877,467.29 | 104,506,851.42 |
| 资产处置收益 | 3,732.45 | - | - | 637,786.38 |
| 资产减值损失(新) | 313,557.02 | 536,333.46 | 1,699,906.84 | -19,708,750.29 |
| 信用减值损失(新) | -8,657,068.24 | 172,123.76 | -2,867,259.07 | -8,950,967.28 |
| 其他收益 | 36,200,677.46 | 12,954,305.42 | 8,894,839.76 | 89,544,334.04 |
| 四、营业利润 | 940,134,711.63 | 549,675,743.28 | 262,754,207.9 | 1,217,929,013.35 |
| 加:营业外收入 | 2,937,525.03 | 1,899,116.31 | 1,055,929.03 | 20,022,116.23 |
| 减:营业外支出 | 9,811,370.22 | 5,421,474.93 | 1,823,377.28 | 15,184,737.02 |
| 五、利润总额 | 933,260,866.44 | 546,153,384.66 | 261,986,759.65 | 1,222,766,392.56 |
| 减:所得税费用 | 81,722,224.61 | 43,949,283.79 | 22,849,481.09 | 136,382,170.51 |
| 六、净利润 | 851,538,641.83 | 502,204,100.87 | 239,137,278.56 | 1,086,384,222.05 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 851,538,641.83 | 502,204,100.87 | 239,137,278.56 | 1,086,384,222.05 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 847,091,041.28 | 497,124,027.29 | 236,447,362.38 | 1,068,016,468.23 |
| 少数股东损益 | 4,447,600.55 | 5,080,073.58 | 2,689,916.18 | 18,367,753.82 |
| 扣除非经常损益后的净利润 | 827,852,038.87 | 493,172,493.18 | 232,433,248.15 | 998,383,780.15 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 1.48 | 0.87 | 0.41 | 1.87 |
| (二)稀释每股收益 | 1.48 | 0.87 | 0.41 | 1.87 |
| 八、其他综合收益 | -916,506.69 | -331,982.96 | -160,461.9 | -195,065.28 |
| 归属于母公司股东的其他综合收益 | -916,506.69 | -331,982.96 | -160,461.9 | -195,065.28 |
| 九、综合收益总额 | 850,622,135.14 | 501,872,117.91 | 238,976,816.66 | 1,086,189,156.77 |
| 归属于母公司股东的综合收益总额 | 846,174,534.59 | 496,792,044.33 | 236,286,900.48 | 1,067,821,402.95 |
| 归属于少数股东的综合收益总额 | 4,447,600.55 | 5,080,073.58 | 2,689,916.18 | 18,367,753.82 |
| 公告日期 | 2026-10-27 | 2026-08-25 | 2026-04-23 | 2026-04-23 |
| 审计意见(境内) | | | | 标准无保留意见 |